Literature DB >> 15570303

Anti-CD20 monoclonal antibody rituximab for the treatment of B-cell chronic lymphocytic leukemia-associated pure red cell aplasia.

Despina Pantelidou, Costas Tsatalas, Dimitris Margaritis, Vasiliki Kaloutsi, Emmanuel Spanoudakis, George Bourikas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15570303     DOI： 10.1038/sj.thj.6200554

Source DB:  PubMed          Journal:  Hematol J        ISSN： 1466-4860


× No keyword cloud information.
  4 in total

Review 1.  Autoimmune complications in chronic lymphocytic leukaemia (CLL).

Authors:  Clive S Zent; Neil E Kay
Journal:  Best Pract Res Clin Haematol       Date:  2010-03       Impact factor: 3.020

2.  Thymoma with Concomitant Pure Red Cell Aplasia, Good's Syndrome and Myasthenia Gravis Responding to Rituximab.

Authors:  Ahmad I Antar; Zaher K Otrock; Mohamed A Kharfan-Dabaja; Rami A Mahfouz; Raafat S Alameddine; Nadim M W El-Majzoub; Ziad M Salem
Journal:  Indian J Hematol Blood Transfus       Date:  2014-12-11       Impact factor: 0.900

3.  Pure red cell aplasia as first manifestation of splenic marginal zone lymphoma-successful treatment with rituximab: a case report.

Authors:  Athanasios Anastasiadis; Dimitrios Margaritis; Ioannis Kotsianidis; Emmanouil Spanoudakis; Anna Christoforidou; Ioannis Kostopoulos; Constantinos Tsatalas
Journal:  Cases J       Date:  2009-08-18

Review 4.  Acquired pure red cell aplasia: updated review of treatment.

Authors:  Kenichi Sawada; Naohito Fujishima; Makoto Hirokawa
Journal:  Br J Haematol       Date:  2008-05-28       Impact factor: 6.998
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.